CYP21A2 mutations in pediatric patients with congenital adrenal hyperplasia in Costa Rica

• Published in: Molecular genetics and metabolism reports Vol. 27; p. 100728
• Main Authors: Umaña-Calderón, Andrés, Acuña-Navas, María José, Alvarado, Danny, Jiménez, Mildred, Cavallo-Aita, Fred
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.06.2021; Elsevier
• Subjects: 21-hydroxylase; c.292+5G>A; Congenital adrenal hyperplasia; CYP21A2; IVS2+5G>A; Research Paper; c.292+5G>A; IVS2+5G>A; Congenital adrenal hyperplasia; CYP21A2; 21-hydroxylase
• ISSN: 2214-4269; 2214-4269
• DOI: 10.1016/j.ymgmr.2021.100728

Steroid 21-hydroxylase deficiency accounts for 95% of congenital adrenal hyperplasia (CAH) cases. Newborn screening has allowed for early detection of the disease, and currently, molecular analysis can identify the genotypes of these patients. Phenotype-genotype correlation has been well described in previous studies. In Costa Rica, there is no data about the genetic background of these patients, nor their phenotypic correlation. Observational, retrospective, descriptive study based on the review of patient records who had a diagnosis of CAH and were performed molecular analysis using gene sequencing or MLPA during the period from 2006 to 2018 (N = 58). To describe the clinical and genetic characteristics of CAH patients due to 21-hydroxylase deficiency at the National Children's Hospital “Dr. Carlos Sáenz Herrera”, Caja Costarricense de Seguro Social (CCSS) in Costa Rica. 53% (31/58) of the patients were male and 80% (37/46) were born full term; 72% (42/58) had salt wasting phenotype, 9% (5/58) simple virilizing phenotype and 19% (11/58) non-classic phenotype. The most frequent variants were c.292+5G>A in 26% (15/58) of patients and Del/Del in 21% (12/58) of them. The most frequent mutation in our study population was the c.292+5G>A, which was found in 15/58 patients. This rare variant has only been reported in three other studies so far but as an infrequent mutation in CAH patients. The genetic characteristics of Costa Rican patients differ from what has been documented worldwide and could respond to a founder effect.